A Phase 2 interventional study of ORX750 and ORX750 in Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia, sponsored by Centessa Pharmaceuticals (UK) Limited. Recruiting at 24 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Centessa Pharmaceuticals (UK) Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 26th registered.
53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.
Browse Idiopathic Hypersomnia studies →12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
Takeda · Sites in United States, Australia, China and 2 more countries
Ages 18–71
University of Pittsburgh · Sites in United States
Ages 18+ · Healthy volunteers
Harmony Biosciences Management, Inc. · Sites in United States, Canada
Ages 18+
Takeda · Sites in United States, France, Hong Kong and 3 more countries
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 8 · Phase 4 2
First in 2010; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 82 across 40 interventional studies indexed under Idiopathic Hypersomnia.
Median enrollment 100 across the 27 interventional studies, 100 across the 3 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Centessa Pharmaceuticals (UK) Limited, one of the names counted as Eli Lilly and Company. Under that name alone:
Centessa Pharmaceuticals (UK) Limited is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Eli Lilly and Company has 2 studies filed under Idiopathic Hypersomnia — fewer than ten, so there is no comparison to draw.
5 of the studies in Idiopathic Hypersomnia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500090Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) | 2027-10 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT06812078TakedaA Study of TAK-360 in Adults With Idiopathic Hypersomnia | 2026-11-30 |
| NCT06752668Centessa Pharmaceuticals (UK) LimitedA Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia | 2026-12 |
| NCT05837091Mayo ClinicLow Sodium Oxybate in Patients With Idiopathic Hypersomnia | 2027-01-29 |
Add all 5 to your calendar (.ics) → With an account.
Among the 30 studies in Idiopathic Hypersomnia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Narcolepsy Type 1 (Open Label)
Drug: ORX750
Narcolepsy Type 2 (Open Label)
Drug: ORX750
Idiopathic Hypersomnia (Open Label)
Drug: ORX750
Oral ORX750
Oral ORX750
Oral ORX750
Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Time frame: Up to day 70
Abnormal Laboratory Tests
Number of Participants With Abnormal Changes From Baseline in Laboratory Tests
Time frame: Up to day 70
Abnormal Vital Signs
Number of Participants With Abnormal Change From Baseline in Vital Signs
Time frame: Up to day 70
Abnormal ECG
Number of Participants With Abnormal Change From Baseline in Electrocardiograms (ECG)
Time frame: Up to day 70
Suicidal Ideation or Behavior
Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
Time frame: Up to day 70
Cmax
Cmax: Maximum Observed Plasma Concentration for ORX750
Time frame: Up to day 63
Tmax
Tmax: Time of Maximum Concentration for ORX750
Time frame: Up to day 63
AUClast
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for ORX750
Time frame: Up to day 63
Cmax,ss
Cmax,ss: Maximum Observed Concentration at Steady State for ORX750
Time frame: Up to day 63
AUCτ
AUCτ: Area Under the Concentration-time Curve During a Dosing Interval at Steady State for ORX750
Time frame: Up to day 63
Maintenance of Wakefulness Test
Change From Baseline in Mean sleep latency (average of the first 4 trials) in the Maintenance of Wakefulness Test (MWT)
Time frame: Up to day 63
Epworth Sleepiness Scale
Change From Baseline in Epworth Sleepiness Scale (ESS)
Time frame: Up to day 63
Started Aug 2025 (actual). Primary completion is estimated for Apr 2026, 8 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centessa Pharmaceuticals (UK) Limited →